Related Experiment Video
Updated: Sep 13, 2025
06:08
Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
Published on: September 8, 2023
1.4K
Neutralization Activity of Standard and Hyperimmune Intravenous Immunoglobulins Against Recently Circulating
Dongxiao Liu1, Lorenza Bellusci1, Hana Golding1
1Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.
Vaccines
|July 30, 2025
Summary
Recent Intravenous Immunoglobulin (IVIG) lots contain antibodies effective against current Omicron variants like KP.3 and XEC. These newer IVIG preparations may offer protection against COVID-19 from these evolving SARS-CoV-2 strains.
Area of Science:
- Immunology
- Virology
- Infectious Diseases
Background:
- Circulating SARS-CoV-2 Omicron variants, such as KP.3 and XEC, exhibit resistance to neutralization by antibodies from earlier convalescent plasma and IVIG preparations.
- The emergence of immune-evasive variants necessitates the evaluation of updated therapeutic countermeasures.
Purpose of the Study:
- To assess the neutralizing antibody activity in recent Intravenous Immunoglobulin (IVIG) lots against currently circulating Omicron variants.
- To determine the potential protective efficacy of contemporary IVIG against COVID-19 caused by SARS-CoV-2 variants like KP.3 and XEC.
Main Methods:
- Analysis of neutralizing antibodies present in IVIG lots manufactured between 2023 and 2024.
- Testing the efficacy of these IVIG preparations against specific Omicron subvariants, including KP.3 and XEC.
Main Results:
- IVIG lots produced in 2023-2024 possess neutralizing antibodies targeting circulating Omicron variants.
- These antibodies are effective against variants like KP.3 and XEC, which are resistant to pre-2023 IVIG and convalescent plasma.
Conclusions:
- Recent IVIG preparations contain antibodies capable of neutralizing contemporary SARS-CoV-2 Omicron variants.
- These findings suggest that current IVIG formulations may offer a degree of protection against COVID-19 caused by prevalent and evolving SARS-CoV-2 strains.
